Skip to main content

Erratum to: Dual HER2 blockade: preclinical and clinical data

The Original Article was published on 31 July 2014

Abstract

No abstract.

Erratum

After publication of our review [1], we noted errors to the legend of Figure 1B, C. The ado-trastuzumab-emtansine concentration should be 1 μg/ml instead of 1 mg/ml. The trastuzumab concentration should be 10 μg/ml instead of 10 mg/ml. The lapatinib concentration should be 10 μM instead of 10 mM (Please see Figure 1, a corrected version of the original Figure 1).

Figure 1
figure 1

Dual blockade with antibody–drug conjugate and targeted therapy. (A) SCID Beige mice were injected with 1 million cells per mouse in the estrogen receptor-positive, human epidermal growth factor receptor (HER)-positive cell line called BT474-m1. These animals were randomized into six groups and treated with: vehicle control; trastuzumab (5 mg/kg once weekly); lapatinib (100 mg/kg daily); ado-trastuzumab-emtansine (TDM-1; 5 mg/kg weekly); trastuzumab (5 mg/kg once weekly) + lapatinib (100 mg/kg daily); or TDM-1 (5 mg/kg weekly) + lapatinib (100 mg/kg daily). Tumor volume fold-change will be measured twice weekly post treatment. (B), (C) BT474 and SKBR3 HER2-positive cell lines were treated with the following: vehicle control; TDM-1 (1 μg/ml); trastuzumab (10 μg/ml) + lapatinib (10 μM) 4); or TDM-1 (1 μg/ml) + lapatinib (10 μM). Cells were assessed for proliferation and apoptosis post treatment. *Data analyzed by one way analysis of variance followed by Tukey analysis for a pairwise comparison of different groups, P < 0.05. T, trastuzumab; L, lapatinib. Data from J Chang, unpublished data.

References

  1. Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res. 2014, 16: 419-10.1186/s13058-014-0419-5.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jenny C Chang.

Additional information

The online version of the original article can be found at 10.1186/s13058-014-0419-5

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patel, T.A., Dave, B., Rodriguez, A.A. et al. Erratum to: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res 16, 468 (2014). https://doi.org/10.1186/s13058-014-0468-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13058-014-0468-9